Structural Characterization Techniques
- Explain how UV-Visible and FTIR spectroscopy contribute preliminary structural information.
- Describe the principle of NMR spectroscopy and the complementary information provided by 1D and 2D experiments.
- Explain the principle of mass spectrometry and the additional structural confidence provided by HRMS.
- Describe LC-MS/MS and GC-MS as hyphenated techniques combining separation with mass detection.
- Explain how spectral data from multiple techniques is integrated to confirm molecular structure.
Ultraviolet-visible spectroscopy measures the absorption of light in the 200–800 nanometre range arising from electronic transitions within a molecule's chromophoric system, most commonly involving conjugated pi-electron systems and lone-pair-bearing heteroatoms. The wavelength of maximum absorption, λmax, together with the molar extinction coefficient, provides preliminary information about the extent of molecular conjugation and, for compounds bearing an extended chromophore, can offer an early indication of successful synthesis or structural modification through observed shifts in absorption maxima. Although UV-Vis spectroscopy alone rarely provides sufficient structural detail for unambiguous compound identification, it remains a rapid, inexpensive, first-line confirmatory technique and additionally underlies UV detection in the chromatographic purity and quantification methods addressed in Phase 4 of this text.
Fourier-transform infrared spectroscopy identifies the functional groups present within a molecule by their characteristic vibrational absorption frequencies across the 4000–400 cm⁻¹ range, with each distinct functional group — hydroxyl, carbonyl, amine, aromatic, and others — producing absorption in a well-established, diagnostic frequency region. FTIR is typically performed as one of the earliest confirmatory analyses following a synthetic reaction, since the appearance or disappearance of a characteristic functional-group absorption (for example, the emergence of a carbonyl stretch near 1700–1750 cm⁻¹ following an oxidation reaction) provides rapid, qualitative confirmation that the intended transformation has occurred, ahead of the more detailed and time-consuming NMR and mass spectrometric analysis that follows.
Nuclear magnetic resonance spectroscopy exploits the intrinsic magnetic property (spin) of certain atomic nuclei, most importantly hydrogen-1 and carbon-13 in organic structure elucidation, which resonate at a characteristic radiofrequency when placed within a strong external magnetic field. The precise resonance frequency of a given nucleus, expressed as its chemical shift relative to a reference standard (conventionally tetramethylsilane), is sensitively influenced by the surrounding electronic environment, allowing NMR to report directly on the local chemical environment of every distinct hydrogen and carbon atom within a molecule and thereby providing the single most information-rich structural technique available to the medicinal chemist.
Proton (¹H) NMR, typically recorded at 400–600 MHz field strength, resolves the chemical shift, integration (relative proton count), multiplicity (splitting pattern arising from coupling to neighbouring protons), and coupling constant of every distinct proton environment, together providing detailed information about both the local chemical environment and the connectivity between adjacent protons. Carbon-13 (¹³C) NMR resolves the complete carbon skeleton of a molecule, though with inherently lower sensitivity than proton NMR owing to the low natural abundance of the carbon-13 isotope, typically requiring proton decoupling to simplify the resulting spectrum into a series of single resonances. The DEPT (Distortionless Enhancement by Polarisation Transfer) experiment further refines carbon-13 analysis by distinguishing carbon multiplicity directly from the spectrum: methyl and methine carbons appear as positive signals, methylene carbons appear as negative (inverted) signals, and quaternary carbons, lacking any attached proton, disappear entirely, providing immediate and unambiguous carbon-type assignment without requiring separate coupled and decoupled spectra.
Two-dimensional NMR experiments correlate pairs of nuclei through their mutual coupling or spatial proximity, providing the connectivity information required for unambiguous structure elucidation of complex or novel molecules that cannot be resolved by one-dimensional spectra alone. COSY (Correlation Spectroscopy) correlates protons that are mutually coupled through, typically, two or three chemical bonds, directly revealing proton–proton connectivity across the molecular framework. HSQC (Heteronuclear Single Quantum Coherence) correlates each proton with the single carbon atom to which it is directly bonded, providing an unambiguous one-bond proton–carbon assignment map. HMBC (Heteronuclear Multiple Bond Correlation) correlates protons with carbons separated by two to three bonds, and is particularly valuable for establishing connectivity across quaternary carbons and heteroatoms that HSQC, limited to one-bond correlations, cannot directly address; the combination of COSY, HSQC, and HMBC data is typically sufficient to construct a complete, unambiguous connectivity map even for a structurally novel compound with no close literature precedent.
The illustration should show a representative small-molecule structure alongside its annotated COSY, HSQC, and HMBC correlation network, using arrows or dashed lines to indicate which specific proton-proton or proton-carbon pairs give rise to each correlation type, demonstrating how the three experiments together establish complete molecular connectivity.
Complete NMR characterisation of every synthesised intermediate and final compound is performed not merely as a formal record-keeping exercise but because it provides the direct, atom-level evidence that a proposed synthetic transformation has actually produced the intended structure, rather than an isomeric, rearranged, or otherwise unexpected product. From a research perspective, NMR data underlies the confident reporting of a novel synthetic method or a newly characterised structure–activity relationship; from an industrial and regulatory perspective, complete and unambiguous structural confirmation of an active pharmaceutical ingredient and its synthetic intermediates is a foundational expectation of any regulatory submission, since the safety and efficacy data generated in later development stages is only meaningful if the chemical identity of the tested compound has been rigorously confirmed.
Modern NMR spectrometers operate at field strengths ranging from 300 MHz for routine structural confirmation to 600 MHz or higher for the more demanding two-dimensional experiments required for complex or novel structure elucidation, with higher field strength generally providing improved spectral resolution and sensitivity. Sample preparation requires dissolution in a deuterated solvent — commonly deuterochloroform (CDCl3) for moderately lipophilic organic compounds or deuterated dimethyl sulfoxide (DMSO-d6) for more polar or poorly chloroform-soluble compounds — chosen to avoid interference with the analyte's own proton and carbon signals. Systematic spectral interpretation typically proceeds by first assigning all readily identifiable proton and carbon signals from one-dimensional spectra, then using two-dimensional correlation data to establish connectivity between the remaining, more ambiguous signals, and finally cross-checking the fully assigned structure against the molecular formula independently established by mass spectrometry, described in the following section.
Mass spectrometry determines the molecular mass of a compound, and through analysis of its characteristic fragmentation pattern, provides additional structural information about the connectivity and substitution pattern of the molecule. A sample is ionised (most commonly, for pharmaceutical compounds, by electrospray ionisation, a soft ionisation technique that produces predominantly intact molecular ions with minimal fragmentation) and the resulting ions are separated and detected according to their mass-to-charge ratio, yielding a mass spectrum in which the molecular ion peak (commonly observed as [M+H]⁺ in positive-ion mode or [M−H]⁻ in negative-ion mode) directly indicates molecular weight, while characteristic fragment ions arising from cleavage at particularly labile bonds provide corroborating structural evidence.
High-resolution mass spectrometry measures mass-to-charge ratio with sufficient precision — typically to within a few parts per million — to distinguish between molecular formulae of very similar nominal mass, thereby allowing the exact molecular formula of a compound to be determined directly from its measured mass rather than merely inferred. This capability is of particular importance in medicinal chemistry structure confirmation, since two structurally distinct compounds can readily share an identical nominal (unit) mass while differing at the fourth or fifth decimal place in exact mass, a distinction only high-resolution instrumentation such as time-of-flight (TOF) or Orbitrap mass analysers can reliably resolve; HRMS data, reported alongside the calculated exact mass for the proposed molecular formula and the observed mass accuracy in parts per million, is now considered a standard requirement for reporting a novel synthesised compound in the medicinal chemistry literature.
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) combines chromatographic separation with sequential stages of mass analysis, in which a selected precursor ion is isolated, deliberately fragmented through collision-induced dissociation, and the resulting product ions are analysed in a second mass-analysis stage, providing both separation of complex mixtures and highly specific, structurally informative detection of each individual component. LC-MS/MS is of central importance not only in structural characterisation but throughout pharmaceutical development more broadly, underlying pharmacokinetic bioanalysis (quantifying drug and metabolite concentration in biological matrices), impurity identification during analytical method development, and metabolite identification studies, owing to its combination of chromatographic resolving power with the exceptional sensitivity and specificity of tandem mass detection.
Gas chromatography coupled to mass spectrometry (GC-MS) applies the same hyphenated separation-and-detection principle to volatile and thermally stable compounds amenable to gas-phase chromatographic separation, and is particularly well suited within medicinal chemistry practice to residual solvent analysis (addressed in detail in Phase 4), volatile synthetic intermediate characterisation, and the identification of volatile impurities that would not be amenable to liquid chromatographic analysis. Electron ionisation, the standard GC-MS ionisation technique, produces extensive, highly reproducible fragmentation that, unlike the soft ionisation typically used in LC-MS, generates rich structural information directly from the fragmentation pattern itself and allows unknown compounds to be identified with high confidence by comparison against extensive, well-established reference spectral libraries.
Definitive structure confirmation of a synthesised compound integrates evidence from every spectroscopic and spectrometric technique described in this phase into a single, internally consistent structural conclusion, rather than relying on any individual technique in isolation. The standard integrated interpretation workflow begins with mass spectrometry (typically HRMS) to establish the molecular formula; proceeds through FTIR to confirm the presence of expected functional groups and the absence of unexpected ones (such as a residual starting-material functional group indicating incomplete reaction); and concludes with complete one- and two-dimensional NMR analysis to establish the full atom-by-atom connectivity and, where relevant, stereochemistry of the molecule. A structure is considered definitively confirmed only when every piece of spectroscopic evidence — molecular formula, functional group pattern, and complete NMR connectivity — is mutually consistent with a single proposed structure and inconsistent with any plausible alternative isomeric structure; any unresolved discrepancy between techniques must be actively investigated and resolved, rather than selectively disregarded, before a structure is reported with confidence.
While the techniques described in this phase characterise the small-molecule compound itself, complementary structural biology techniques — X-ray crystallography of a ligand–target co-crystal, and increasingly cryo-electron microscopy for large or membrane-embedded targets historically resistant to crystallisation — directly visualise how the synthesised and characterised compound engages its biological target, closing the loop between the computational design described in Phase 1 and the biological activity data generated later in the discovery pipeline. The growing accessibility of cryo-EM, driven by advances in detector technology and computational image processing, has substantially expanded the range of pharmaceutically important targets, including GPCRs and ion channels in defined conformational states, for which high-resolution structural data can now inform structure-based medicinal chemistry design.
Why is HRMS considered a stronger structural proof than standard (low-resolution) mass spectrometry?
Standard mass spectrometry confirms only the nominal (integer) molecular weight, which can be shared by multiple distinct molecular formulae; HRMS measures mass with sufficient precision to distinguish between these formulae directly, providing considerably stronger evidence for a specific proposed structure.
Is NMR alone ever sufficient to confirm a novel compound's structure without mass spectrometric data?
No — regulatory and publication standards consistently require independent molecular formula confirmation by mass spectrometry alongside NMR connectivity data, since NMR alone cannot rule out certain isomeric possibilities that share an identical connectivity pattern but differ in molecular formula, such as compounds differing by a water or halogen substitution.
- Explain why DEPT is able to distinguish CH, CH2, and CH3 carbons but not quaternary carbons.
- What structural information does HMBC provide that HSQC cannot, and why?
- Why is electrospray ionisation described as a 'soft' ionisation technique?
- Differentiate nominal mass from exact mass and explain the significance of this distinction for HRMS.
- Why is GC-MS preferred over LC-MS for residual solvent analysis?
- Describe the standard integrated workflow used to confirm the structure of a newly synthesised compound.
A common interpretive error is assigning a tentative NMR structure based on chemical shift and multiplicity alone without cross-referencing two-dimensional connectivity data, risking a plausible but ultimately incorrect structural assignment, particularly for compounds bearing multiple similar substituents. Broad, poorly resolved NMR signals are most often attributable to sample impurity, residual paramagnetic contamination, or the use of an inappropriate deuterated solvent for the compound's solubility profile, and are best resolved by re-purifying the sample and confirming solvent choice before questioning the underlying chemical structure. Where a mass spectrum fails to show a clear molecular ion peak, acquiring the spectrum under both positive- and negative-ion electrospray conditions, or supplementing with an alternative ionisation technique such as atmospheric pressure chemical ionisation, will frequently resolve the ambiguity.